• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

以 4ng/mL 为截断值的前列腺特异性抗原在医院环境中诊断前列腺癌的诊断准确性:系统评价和荟萃分析。

Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis.

机构信息

National Evidence-based Healthcare Collaborating Agency, Seoul, Korea.

Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea.

出版信息

Investig Clin Urol. 2022 May;63(3):251-261. doi: 10.4111/icu.20210429.

DOI:10.4111/icu.20210429
PMID:35534215
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9091828/
Abstract

PURPOSE

A prostate-specific antigen (PSA) cutoff of 4 ng/mL has been widely used for prostate cancer screening in population-based settings. However, the accuracy of PSA below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting is inconclusive. We systematically reviewed the accuracy of PSA below 4 ng/mL cutoff in a hospital setting.

MATERIALS AND METHODS

We systematically reviewed the literature by searching major databases until March 2020, and a meta-analysis and quality assessment were performed.

RESULTS

A total of 11 studies were included at the completion of the screening process. The meta-analysis showed a sensitivity of 0.92 and a specificity of 0.16 for a PSA cutoff below 4 ng/mL. The area under the hierarchical summary receiver operating characteristic curve was 0.87, the positive likelihood ratio was 1.23, the negative likelihood ratio was 0.46, and the diagnostic odds ratio was 2.64. PSA sensitivities and specificities varied according to the cutoff range: 0.94 and 0.17 for 2 to 2.99 ng/mL, and 0.92 and 0.16 for 3 to 3.99 ng/mL, respectively. No significant differences in the sensitivity and specificity of PSA cutoffs in the range of 2 to 2.99 ng/mL and 3 to 3.99 ng/mL were found.

CONCLUSIONS

Although a PSA cutoff <3 ng/mL is relatively more sensitive and specific than PSA ≥3 ng/mL, no significant differences in sensitivity and specificity were found in the diagnosis of prostate cancer. Therefore, clinicians should choose an appropriate PSA cutoff on the basis of clinical circumstances and patients' characteristics.

摘要

目的

在基于人群的前列腺癌筛查中,前列腺特异性抗原(PSA)的截断值为 4ng/ml 已被广泛应用。然而,在医院环境中,PSA 截断值在 4ng/ml 以下诊断前列腺癌的准确性尚不确定。我们系统地回顾了 PSA 截断值在 4ng/ml 以下的医院环境中的准确性。

材料与方法

我们系统地检索了主要数据库的文献,直到 2020 年 3 月,并进行了荟萃分析和质量评估。

结果

在完成筛选过程后,共有 11 项研究纳入。荟萃分析显示,PSA 截断值在 4ng/ml 以下的敏感性为 0.92,特异性为 0.16。分层综合接收者操作特征曲线下的面积为 0.87,阳性似然比为 1.23,阴性似然比为 0.46,诊断比值比为 2.64。根据截断范围,PSA 的敏感性和特异性不同:2 至 2.99ng/ml 时为 0.94 和 0.17,3 至 3.99ng/ml 时为 0.92 和 0.16。在 2 至 2.99ng/ml 和 3 至 3.99ng/ml 范围内,PSA 截断值的敏感性和特异性无显著差异。

结论

尽管 PSA 截断值<3ng/ml 比 PSA≥3ng/ml 更敏感和特异,但在前列腺癌的诊断中,敏感性和特异性无显著差异。因此,临床医生应根据临床情况和患者特征选择合适的 PSA 截断值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b0/9091828/39163cc2fb04/icu-63-251-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b0/9091828/12ee2ba346b8/icu-63-251-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b0/9091828/39163cc2fb04/icu-63-251-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b0/9091828/12ee2ba346b8/icu-63-251-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c3b0/9091828/39163cc2fb04/icu-63-251-g002.jpg

相似文献

1
Diagnostic accuracy of prostate-specific antigen below 4 ng/mL as a cutoff for diagnosing prostate cancer in a hospital setting: A systematic review and meta-analysis.以 4ng/mL 为截断值的前列腺特异性抗原在医院环境中诊断前列腺癌的诊断准确性:系统评价和荟萃分析。
Investig Clin Urol. 2022 May;63(3):251-261. doi: 10.4111/icu.20210429.
2
The cutoff level of free/total prostate specific antigen (f/t PSA) ratios in the diagnosis of prostate cancer: a validation study on a Turkish patient population in different age categories.游离/总前列腺特异性抗原(f/t PSA)比值在前列腺癌诊断中的临界值:对不同年龄组土耳其患者群体的验证研究
Kaohsiung J Med Sci. 2014 Nov;30(11):545-50. doi: 10.1016/j.kjms.2014.03.008. Epub 2014 Apr 20.
3
Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.复合前列腺特异性抗原、游离前列腺特异性抗原及其比值在前列腺癌检测中的对比分析
J Urol. 2002 May;167(5):2017-23; discussion 2023-4. doi: 10.1016/s0022-5347(05)65075-6.
4
Value of free/total prostate-specific antigen (f/t PSA) ratios for prostate cancer detection in patients with total serum prostate-specific antigen between 4 and 10 ng/mL: A meta-analysis.总血清前列腺特异性抗原水平在4至10 ng/mL之间的患者中,游离/总前列腺特异性抗原(f/t PSA)比值对前列腺癌检测的价值:一项荟萃分析。
Medicine (Baltimore). 2018 Mar;97(13):e0249. doi: 10.1097/MD.0000000000010249.
5
Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.与总前列腺特异性抗原相比,复合前列腺特异性抗原在检测前列腺癌时能显著提高特异性。
J Urol. 2000 May;163(5):1476-80.
6
Prostate-specific antigen testing accuracy in community practice.社区医疗中前列腺特异性抗原检测的准确性。
BMC Fam Pract. 2002 Oct 24;3:19. doi: 10.1186/1471-2296-3-19.
7
Efficiency of prostate-specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age-specific reference range as a cutoff for abnormal values.以4.0 ng/ml及年龄特异性参考范围作为异常值的临界值时,前列腺特异性抗原和直肠指检在筛查中的效率。
Prostate. 1999 Mar 1;38(4):296-302. doi: 10.1002/(sici)1097-0045(19990301)38:4<296::aid-pros5>3.0.co;2-p.
8
Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands.通过前列腺特异性抗原(PSA)进行前列腺癌筛查;对开曼群岛的少数人群而言是一种切实可行的方法。
Cancer Causes Control. 2018 Jan;29(1):87-92. doi: 10.1007/s10552-017-0963-2. Epub 2017 Sep 16.
9
Usefulness of age-specific reference range of prostate-specific antigen for Japanese men older than 60 years in mass screening for prostate cancer.前列腺特异性抗原年龄特异性参考范围对60岁以上日本男性前列腺癌大规模筛查的效用。
Urology. 2000 Aug 1;56(2):278-82. doi: 10.1016/s0090-4295(00)00613-0.
10
Utility of volume adjusted prostate specific antigen density in the diagnosis of prostate cancer in Arab men.体积校正前列腺特异性抗原密度在阿拉伯男性前列腺癌诊断中的应用
Int Urol Nephrol. 2005;37(4):721-6. doi: 10.1007/s11255-005-4683-2.

引用本文的文献

1
A Proof-of-Concept Study on Bioelectric-Based Biosensing for Prostate-Specific Antigen Detection in Serum Samples.基于生物电的生物传感用于血清样本中前列腺特异性抗原检测的概念验证研究。
Biosensors (Basel). 2025 Aug 3;15(8):503. doi: 10.3390/bios15080503.
2
Blood-Based DNA Methylation Analysis by Multiplexed OBBPA-ddPCR to Verify Indications for Prostate Biopsies in Suspected Prostate Cancer Patients.通过多重OBBPA-ddPCR进行基于血液的DNA甲基化分析,以验证疑似前列腺癌患者前列腺活检的指征。
Cancers (Basel). 2024 Mar 28;16(7):1324. doi: 10.3390/cancers16071324.
3
New insights on the early prostate cancer diagnosis in a real-world setting.

本文引用的文献

1
Strategy for Prostate Cancer Patients with Low Prostate Specific Antigen Level (2.5 to 4.0 ng/mL).前列腺特异性抗原水平(2.5 至 4.0ng/ml)较低的前列腺癌患者的治疗策略。
J Korean Med Sci. 2020 Oct 26;35(41):e342. doi: 10.3346/jkms.2020.35.e342.
2
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer.EAU-EANM-ESTRO-ESUR-SIOG 前列腺癌诊治指南。第二部分-2020 年更新:复发性和转移性前列腺癌的治疗。
Eur Urol. 2021 Feb;79(2):263-282. doi: 10.1016/j.eururo.2020.09.046. Epub 2020 Oct 7.
3
Diagnostic Accuracy Studies.
真实世界中早期前列腺癌诊断的新见解。
Investig Clin Urol. 2022 May;63(3):248-250. doi: 10.4111/icu.20220041.
诊断准确性研究。
Semin Nucl Med. 2019 Mar;49(2):87-93. doi: 10.1053/j.semnuclmed.2018.11.005. Epub 2018 Dec 13.
4
Impact of PSA density of transition zone as a potential parameter in reducing the number of unnecessary prostate biopsies in patients with psa levels between 2.6 and 10.0 ng/mL.探讨 PSA 密度在 PSA 水平 2.6-10.0ng/ml 之间的患者中作为减少不必要前列腺活检数量的潜在参数的影响。
Int Braz J Urol. 2018 Jul-Aug;44(4):709-716. doi: 10.1590/S1677-5538.IBJU.2017.0506.
5
National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?国家综合癌症网络®有利的中危前列腺癌——是否适合主动监测?
J Urol. 2018 May;199(5):1196-1201. doi: 10.1016/j.juro.2017.12.049. Epub 2017 Dec 26.
6
Lifestyle Risk Prediction Model for Prostate Cancer in a Korean Population.基于韩国人群的前列腺癌生活方式风险预测模型
Cancer Res Treat. 2018 Oct;50(4):1194-1202. doi: 10.4143/crt.2017.484. Epub 2017 Dec 21.
7
Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.[-2]前列腺特异性抗原(p2psa)及其衍生物在2.0至10.0 ng/mL前列腺特异性抗原(PSA)范围内对前列腺癌检测的预测价值。
Int Braz J Urol. 2017 Jan-Feb;43(1):48-56. doi: 10.1590/S1677-5538.IBJU.2016.0256.
8
Clarifying the PSA grey zone: The management of patients with a borderline PSA.明确前列腺特异性抗原(PSA)灰色地带:PSA临界值患者的管理
Int J Clin Pract. 2016 Nov;70(11):950-959. doi: 10.1111/ijcp.12883. Epub 2016 Sep 27.
9
Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.前列腺癌:ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2015 Sep;26 Suppl 5:v69-77. doi: 10.1093/annonc/mdv222. Epub 2015 Jul 22.
10
Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.确定前列腺特异性抗原阈值水平以优化磁共振成像/超声融合引导活检对临床显著性前列腺癌的检测
J Urol. 2014 Dec;192(6):1642-8. doi: 10.1016/j.juro.2014.08.002. Epub 2014 Aug 9.